ARNA:NSD-Arena Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 73.69

Change

0.00 (0.00)%

Market Cap

USD 4.25B

Volume

0.69M

Average Target Price

USD 85.67 (+16.25%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California. Address: 6154 Nancy Ridge Drive, San Diego, CA, United States, 92121

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

N/A

USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

N/A

USD32.18B N/A N/A
MRNA Moderna, Inc

N/A

USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

N/A

USD24.87B N/A N/A
RPRX Royalty Pharma plc

N/A

USD24.33B 36.15 9.83
GMAB Genmab A/S

N/A

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

N/A

USD19.73B N/A N/A
INCY Incyte Corporation

N/A

USD18.93B 47.64 35.20

ETFs Containing ARNA

Symbol Name Weight Mer Price(Change) Market Cap
ROGS Hartford Multifactor Glob.. 0.00 % 0.34 %

N/A

USD0.02B
VALX Validea Market Legends ET.. 0.00 % 0.79 %

N/A

USD0.01B
YOLO AdvisorShares Pure Cannab.. 0.00 % 0.74 %

N/A

USD0.05B
CNBS Amplify Seymour Cannabis .. 0.00 % 0.75 %

N/A

N/A
THCX The Cannabis ETF 0.00 % 0.70 %

N/A

N/A
ROSC Hartford Multifactor Smal.. 0.00 % 0.34 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 62.24% 82% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.24% 82% B- 88% B+
Trailing 12 Months  
Capital Gain 61.25% 72% C- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.25% 72% C- 85% B
Trailing 5 Years  
Capital Gain 247.59% 88% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 247.59% 88% B+ 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 42.82% N/A N/A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.82% N/A N/A 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 66.42% N/A N/A 16% F
Risk Adjusted Return 64.47% N/A N/A 80% B-
Market Capitalization 4.25B 92% A- 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 6.40 51% F 81% B-
Price/Book Ratio 3.39 56% F 36% F
Price / Cash Flow Ratio 7.47 9% F 35% F
EV/EBITDA 3.52 38% F 87% B+
Management Effectiveness  
Return on Equity -28.34% 83% B 32% F
Return on Invested Capital 42.02% 97% A+ 97% A+
Return on Assets -17.42% 75% C 22% F
Debt to Equity Ratio 4.26% 76% C 84% B
Technical Ratios  
Short Ratio 8.17 30% F 18% F
Short Percent 6.69% 48% F 31% F
Beta 1.27 61% D- 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.